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Synthesis of a novel HER2 targeted aza-BODIPY–antibody 
conjugate: Synthesis, photophysical characterisation and in vitro 
evaluation.  
Miffy. H. Y. Cheng,a Antoine Maruani,b Huguette Savoie,a  Vijay Chudasamab* and Ross. W. Boylea* 
We herein report the synthesis and analysis of a novel aza-BODIPY–antibody conjugate, formed by controlled and 
regioselective bioconjugation methodology. Employing the clinically relevant antibody, which targets HER2 positive 
cancers, represents an excellent example of an antibody targeting strategy for this class of near-IR emitting fluorophore. 
The NIR fluorescence and binding properties were validated through in vitro studies using live cell confocal imaging.  
Introduction 
Near infrared (NIR) fluorescence imaging has attracted much 
attention over the last decade due to its advantageous properties 
compared to visible region fluorescence. These include deeper 
tissue penetration for in vivo applications, reduced 
autofluorescence and minimisation of light scattering, leading to 
improved signal-to-noise ratios.1 This is of particular interest in 
fluorescence guided surgery (FGS), as the technique can provide a 
stronger contrast between healthy and neoplastic tissues, therefore 
generally improving surgical accuracy.2 Breast conserving surgery is 
an example that can benefit from FGS, as precise identification of 
the tumours is essential for tissue preservation and preventing 
incomplete resection.3 However, many of the current FDA-
approved NIR emitting fluorophores suffer from inaccurate 
targeting and poor photostability, thus limiting their application for 
NIR FGS. Despite many efforts to produce targeted NIR emitting 
fluorophores, poor photophysical properties or solubility issues 
limit their use in biological imaging.4 Therefore, there is a high 
demand for the development of this class of imaging agents with 
improved physicochemical properties.5  
The aza- borondipyrromethenes (BODIPYs) are a relatively new 
class of NIR emitting fluorophores with excellent photostability and 
promising photophysical profile for FGS. Due to their outstanding 
properties, this class of compounds have recently been the subject 
of many biological studies6–10and material based applications11–13. 
In spite of this growing interest, the use of these scaffolds in 
bioconjugation and targeted imaging applications has remained 
limited.14 This is primarily due to the synthetic challenges in 
introducing conjugation moieties15,16 as well as solubility issues 
associated with structural modifications.17Hence, successful 
preparation of antibody– aza-BODIPY-based conjugates has hitherto 
not been achieved. 
Since many tumours have been shown to overexpress receptors, 
both specificity and selectivity can be significantly improved by 
targeting NIR emitting probes to these biomarkers, offering the 
possibility of better contrast and detection of tumours. Monoclonal 
antibodies have been used extensively as targeting moieties in 
biological and clinical research to enhance affinity of drugs and 
imaging agents towards overexpressed receptors in cancerous 
tissues;18,19 they can be covalently bound to fluorescent probes to 
obtain fluorescent antibody conjugates (FAC) for use in 
fluorescence imaging. Several FACs are in preclinical development 
featuring both FDA-approved antibodies and commercially available 
fluorophores.20–23However, FACs are most commonly generated 
through multiple lysine labelling and this methodology results in 
heterogeneous mixtures of products that suffer from variability 
between batches.24 Therefore, this could affect selectivity and 
specificity for target tissue, resulting in poor imaging in FGS. To 
alleviate these issues, site selective bioconjugation methods have 
been developed. A promising approach was recently introduced by 
Chudasama and co-workers 25,26 with the use of 
dibromopyridazinediones (PDs) to regioselectively modify cysteine 
residues through disulfide re-bridging and the applicability of this 
method has been demonstrated in a variety of antibody conjugates. 
26–30 
Herein, we report the synthesis and analysis of a water soluble aza-
BODIPY and its regioselective conjugation to trastuzumab®., a 
clinically relevant monoclonal antibody, in a controlled and efficient 
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method using strained alkyne-functionalised 
dibromopyridazinedione in a copper-free strain-promoted alkyne–
azide cycloaddition (SPAAC) reaction with water soluble azido aza-
BODIPY, and subsequent in vitro validations of the resulting 
conjugate.  
Results and discussion  
Synthesis and characterisation  
Firstly, we explored the synthesis of an azido aza-BODIPY with 
enhanced water solubility, which was compatible with the 
bioconjugation strategy described above. Azide-functionalised aza-
BODIPY 1 was synthesised by adapting a method previously 
reported by our group.31 It was then further modified as shown in 
Scheme 1.  
Briefly, SN2 Williamson ether synthesis was performed at the 
available phenolate to introduce a protected ester, in a 78% yield. 
Deprotection of the t-butyl group was achieved using TFA, the 
reaction was carefully monitored to circumvent removal of BF2 
under acidic conditions, and deprotection was found to be 
complete after 1.5 h, following purification the carboxylic acid 3 
was obtained in 34% yield. To enhance water solubility, an amine 
substituted 5 kDa-PEG chain was reacted with the corresponding 
carboxylic acid 3 through amide coupling in dry DMF at 40 °C for 24 
h. The crude was purified using a C18 cartridge to obtain the water 
soluble aza-BODIPY 4 in 98% yield (Scheme 1).  
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Scheme 1. Synthesis of water soluble azido aza-BODIPY. 
Photophysical studies 
Photophysical evaluation of the aza-BODIPY 4 in aqueous media 
was carried out and showed absorption and emission maxima in 
water at 635 nm and 713 nm respectively. The compound was 
shown to exhibit excellent photostability from the photobleaching 
study through continuous illumination (>600 nm) for 60 minutes at 
10 µM in PBS (pH 7.4), a decrease of 13 % of the absorbance was 
observed for 4; however, this compared favourably with the 
commonly used NIR emitting fluorophore indocyanine green (ICG), 
which showed a 90% decrease under the same conditions after 60 
minutes. (Figure 1). 
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Figure 1. Normalised absorption and emission spectra of 4 in water 
λabs (blue) and λem (red). Photostability study for 4 and ICG in PBS 
(pH 7.4). 
In addition, the fluorescence quantum yield of aza-BODIPY 4 was 
calculated, and was found to be 0.19, this showed slightly lower 
fluorescence quantum yield in comparison to literature values, but 
acceptable as a NIR fluorescence probe (ESI).  
Bioconjugation 
Following on from the successful synthesis and promising 
properties of aza-BODIPY 4, we set about synthesising a “clickable” 
antibody that would enable the controlled and site-selective 
attachment of the imaging moiety. We have recently shown that 
the functional rebridging of trastuzumab disulfide bonds using 
pyridazinedione derivative 5 enabled the preparation of a stable 
and modular platform, 7, that can be functionalised in a rapid and 
facile manner (Figure 2 and Scheme 2).26 The presence of a highly 
and orthogonally reactive strained alkyne moiety makes this 
versatile bioconjugate amenable to copper-free strain-promoted 
alkyne–azide cycloaddition (SPAAC) reaction with a variety of 
substrates.  
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Figure 2. Structure of PD-based re-bridging reagent. 
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Scheme 2. Preparation of “clickable” trastuzumab 7. 
Following preparation of conjugate 7, it was reacted with aza-
BODIPY 4 using SPAAC chemistry (Scheme 3). After optimisation of 
the conditions, it was found that incubation of conjugate 7 with 6 
equivalents (i.e. 1.5 eq per strained alkyne) of aza-BODIPY 4 for 6 h 
at 21 °C, was sufficient to effect complete conversion to aza-
BODIPY–trastuzumab conjugate 8 in near quantitative yield and in 
high purity (see ESI† for details). With aza-BODIPY–trastuzumab 
conjugate 8 in hand, we next appraised its potential as a tool for 
FGS. 
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Scheme 3. Preparation of aza-BODIPY–trastuzumab conjugate 8. 
Cell imaging to produce fluorescence imaging 
To demonstrate the NIR fluorescence imaging properties of 
conjugate 8, in vitro validation was carried out using cells which 
overexpress the HER2 cell surface receptor (BT-474), and another 
cell line which expresses normal levels of the same receptor (MDA-
MB-468) (HER2-), using fluorescence microscopy. The two cell lines 
were individually incubated with 5 µM of 8 for 30 mins at 4 °C. 
Excess conjugate was removed by washing with PBS prior to 
confocal laser scanning microscopy (CLSM) imaging. Figure 3 shows 
that, when excited at 633 nm, intense fluorescence predominately 
localised at the surface of the membrane was observed for BT-474 
cells. Fluorescence was confined to the membrane suggesting 
receptor binding with no non-specific internalisation observed (see 
ESI for z-stack data). A low, but detectable, intensity of fluorescence 
was found for MDA-MB-468 cells. This was expected as these cells 
express native levels of HER2 receptor, rather than overexpressing 
it as suggested by Lawrence at el.32 The calculation of the total 
corrected cellular fluorescence also confirms the significantly higher 
fluorescence seen for BT-474 cells (see ESI).  
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Figure 3. CLSM images of BT-474 (HER2+) and MDA-MB-468 (HER2-) 
incubated with 5 µM conjugate 8 and control. 
Conclusions 
In conclusion, an aza-BODIPY with enhanced water solubility and 
NIR emission was synthesised. Regioselective and 
stoichiometrically-controlled bioconjugation to a clinical relevant 
antibody (trastuzumab®.) generated the first targeted aza-BODIPY–
antibody conjugate. Validation of cell surface receptor binding using 
in vitro CLSM imaging demonstrated selectivity toward HER2 
receptors, highlighting the potentials for aza-BODIPY–antibody 
conjugates as promising NIR fluorescence probes for in vivo imaging 
with promising applications in FGS. 
Experimental  
Materials and methods  
A Jeol JNMLA NMR spectrometer was used to measure 1H NMR at 
400.18 MHz, 19F NMR at 376.54 MHz and 13C NMR at 100.62 MHz, 
the measurement was referenced against standard internal 
tetramethylsilane (TMS). Splitting patterns were written as s 
(singlet), d (doublet), t (triplet) and m (multiplet). The chemical 
shifts (δ) for 1H, 19F and 13C are were measured in ppm. 
Mass spectrum data was obtained from the National Mass 
Spectrometry Service EPSRC, Swansea using LTQ Orbitrap XL mass 
spectrometer. A Varian Cary 50 Bio UV-vis spectrometer was used 
measuring absorptions from 250 nm to 800 nm. A Varian Cary 
Eclipse Fluorescence spectrometer was used measuring excitations 
and emissions from 400 nm to 800 nm.  
Reagents were purchased from Alfa Aesar, ACROS Organic, 
Fluorochem and Sigma Aldrich, and used as received. Dry solvents 
were obtained through drying over molecular sieves applying the 
method of Williams et al.33 Rotary evaporation under reduced 
pressure and a vacuum oven were used to removed excess 
solvents. 
Synthesis of 1 and 5 was carried out in accordance to previously 
described methodology. 31,26 
 
Photostability  
Photostability experiments were conducted in a 46 mm × 12.5 mm 
× 12.5 mm quartz cuvette in PBS p.H 7.4 solution at 298 K under 
continuous illumination direct from above the cuvette for 60 min. 
The NIR light source was a 600 mW Paterson Xenon short arc lamp 
and equipped with a band pass filter to obtain NIR light 685–733 
nm. The intensity of the light from the same distance was measured 
with Macam R203 Radiometer to be 1709.8 Wm-2. Measurement 
was taken every 10 min with a Varian Cary 50 Bio UV-vis 
spectrometer was used measuring absorptions from 250 nm to 800 
nm.   
Fluorescence quantum yield  
Five concentrations with normalised absorptions for compound 8 
was used for this experiment, and calculated using the equation 
below34: 
𝜙𝜙𝑋𝑋 = 𝜙𝜙𝑆𝑆𝑆𝑆 �𝐹𝐹𝑋𝑋{1 − exp(−𝐴𝐴𝑆𝑆𝑆𝑆 ln 10)}𝐹𝐹𝑆𝑆𝑆𝑆{1 − exp(−𝐴𝐴𝑋𝑋 ln 10)}�� 𝜂𝜂𝑋𝑋2𝜂𝜂𝑆𝑆𝑆𝑆2 � 
ΦX is the experimental fluorescence quantum yield of the analyte, 
ΦST is the literature fluorescence quantum yield of the standard, F is 
the integrated fluorescence intensity, A is the absorbance at the 
excitation wavelength, and n is the refractive index of the solvent. 
The two reference systems used were cross-calibrated to obtain 
fluorescein (Φf = 0.98 in 0.1 M NaOH)35 and rhodamine B (Φf = 0.30 
in water).36 
Synthetic procedures 
tert-Butyl 2-(4-(7-(4-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)phenyl)-
5,5-difluoro-1,9-diphenyl-5H-4l4,5l4-dipyrrolo[1,2-c:2',1'-
f][1,3,5,2]triazaborinin-3-yl)phenoxy)acetate (2). A solution aza-
BODIPY 1 (80 mg, 0.12 mmol) in dry DMSO (8 mL) was treated with 
CsF (88 mg, 580 mmol) and tert-butylbromoacetate (280 mg, 0.14 
mmol). The mixture stirred at 40 °C for 3 h. The mixture was then 
cooled in an ice bath to 0 °C, a saturated solution of NH4Cl (12 mL) 
was added and the product extracted with ethyl acetate (2 × 50 
mL). The combined organic layers were washed with brine, dried 
over anhydrous Na2SO4, filtered and the solvent was removed 
under reduced pressure. The crude was purified by column 
chromatography on silica gel (50% EtOAc/hexane) and precipitated 
from hexane over DCM to afford a metallic red solid (72 mg, 78%) Rf 
= 0.51 (silica,5:5, EtOAc:hexane). UV-vis (DCM): λmax, nm (log ε) 660 
(4.98). Fluorescence (DCM): λmax, (exc/ems) nm 660/697. 1H-NMR 
(CDCl3): δ 1.53 (s, 9H, Boc), 3.40 (t, J = 4.9 Hz, 2H, CH2N3), 3.76-
3.63(m, 4H, PEG), 3.83-3.74 (m, 2H, PEG), 3.94 (t, J = 4.8 Hz, 2H, 
PEG) 4.24 (t, J = 4.9 Hz, 2H, PEG), 4.61 (s, 2H, CH2), 6.93 (s, 2H, Py) 
7.00 (dd, J = 8.8, 6.1 Hz, 4H, o-Ar), 7.48-7.46 (m, 6H, m,p-Ph), 8.06-
8.01 (m, 8H, o-Ph, m-Ar). 13C-NMR (CDCl3): δ 28.18 (Boc), 50.78, 
65.73, 67.68, 69.87, 70.23, 70.87, 71.04, 82.75, 114.89, 114.94, 
125.49, 126.26, 128.61, 129.57, 129.59, 129.64, 130.72, 130.79, 
130.95, 131.87, 131.90, 159.18, 160.33, 167.77 (C=O). MS: (APCI) 
m/z 801 (100 [M +H+]), HRMS: 801.3383 calcd. for (C44H44O6N610BF2) 
found 801.3381. 
2-(4-(7-(4-(2-(2-(2-Azidoethoxy)ethoxy)ethoxy)phenyl)-5,5-
difluoro-1,9-diphenyl-5H-4l4,5l4-dipyrrolo[1,2-c:2',1'-
f][1,3,5,2]triazaborinin-3-yl)phenoxy)acetic acid (3). A solution of 
tert-butyl 2-(4-(7-(4-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)phenyl)-
5,5-difluoro-1,9-diphenyl-5H-4l4,5l4-dipyrrolo[1,2-c:2',1'-
f][1,3,5,2]triazaborinin-3-yl)phenoxy)acetate (68 mg, 0.08 mmol) in 
dry DCM (2 mL) was treated with TFA (0.5 mL), and the mixture 
stirred at rt for 1.5 h under Ar before the solvent removed under 
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reduced pressure. The residue was purified by column 
chromatography on silica (DCM to 4% MeOH/DCM) and 
precipitated from hexane over DCM to yield a metallic red solid (15 
mg, 34%). Rf = 0.66 (silica, 10% MeOH:DCM) and 0.29 (silica, 
KNO3:water:MeCN). UV-vis (DCM): λmax, nm (log ε) 660 (4.35). 
Fluorescence (DCM): λmax, (exc/ems) nm 660/693. 1H-NMR (d6-
DMSO): δ 3.67-3.61 (m, 8H, PEG), 3.82 (t, J = 4.5 Hz, 2H, PEG), 4.21 
(t, J = 4.8 Hz, 2H, PEG), 4.80 (s, 2H, CH2), 7.07 (dd, J = 6.7, 8.8 Hz, 4H, 
o-Ar), 7.56 (s, 1H, Py), 7.57 (s, 1H, Py), 7.69-7.57 (m, 6H, m,p-Ph), 
8.12-8.00 (m, 8H, o-Ph, m-Ar). 13C-NMR (d6-DMSO): δ 50.51, 65.08, 
67.82, 69.51, 69.83, 70.25, 70.50, 112.44, 113.46, 115.03, 115.08, 
115.13, 115.23, 115.30, 127.25, 127.29, 129.97, 130.56, 130.66, 
130.69, 131.21, 155.10, 155.71, 170.71 (C=O). 19F-NMR (d6-DMSO): 
δ -130.75 (d, J = 31.3 Hz), -130.91 (d, J = 31.2 Hz). MS: (ESI) m/z 743 
(100 [M -H]-), HRMS: 742.2643 calcd. for (C40H34O6N610BF2) found 
742.2633. 
2-(4-(7-(4-(2-(2-(2-Azidoethoxy)ethoxy)ethoxy)phenyl)-5,5-
difluoro-1,9-diphenyl-5H-4l4,5l4-dipyrrolo[1,2-c:2',1'-
f][1,3,5,2]triazaborinin-3-yl)phenoxy)-N-(2-(2-
methoxyethoxy)ethyl)acetamide (4). 2-(4-(7-(4-(2-(2-(2-
Azidoethoxy)ethoxy)ethoxy)phenyl)-5,5-difluoro-1,9-diphenyl-5H-
4l4,5l4-dipyrrolo[1,2-c:2',1'-f][1,3,5,2]triazaborinin-3-
yl)phenoxy)acetic acid (11 mg, 0.02 mmol), HOBt (11 mg, 0.08 
mmol, 5.3 eq) EDC (11 mg, 0.14 mmol, 9.2 eq), 
methoxypolyethylene glycol amine M.W. 5,000 (115 mg, 0. 02 
mmol, 1.5 eq) and DIPEA (27 µL, 0.31 mmol, 20.5 eq) were 
dissolved in dry DMF (2.2 mL) and the reaction mixture stirred 
overnight at 40 °C. The solvent was then removed under reduced 
pressure and further purified by Sep Pak C18 reverse phase 
cartridge eluting with water and precipitated from DCM over 
diethyl ether to give the product as a yield a dark blue solid. (84 mg, 
98%). Rf = 0.64 (silica, KNO3:water:MeCN). UV-vis (water): λmax, nm 
(log ε) 635 (4.37). Fluorescence (water): λmax, (exc/ems) nm 
635/713. 1H-NMR (CDCl3): δ 3.93-3.36 (m, PEG 5k), 4.23 (s, 2H, CH2), 
6.91 (s, 1H, Py), 6.93 (s, 1H, Py), 7.05-6.96 (m, 4H, o-Ar), 7.52-7.40 
(m, 6H, m,p-Ph), 8.16-7.91 (m, 8H, o-Ph, m-Ar). 19F NMR (CDCl3) δ -
130.72 (d, J = 30.5 Hz), -130.82 (d, J = 31.1 Hz), -130.88 (d, J = 30.7 
Hz), -130.99 (d, J = 31.1 Hz). MS: (MALDI) normal distribution with 
m/z 5649.1. 
Preparation of conjugate 8 
To a solution of trastuzumab (100 μL, 50 μM, 1 eq) in borate buffer 
(25 mM sodium borate, 25 mM NaCl, 0.5 mM EDTA, pH 8.0) was 
added TCEP (final concentration 500 μM, 10 eq) and 5 in DMSO 
(final concentration 1.0 mM, 25 eq) and the reaction mixture 
incubated at 4 °C for 16 h. The excess reagents were then removed 
by repeated diafiltration into fresh buffer using VivaSpin sample 
concentrators (GE Healthcare, 10 000 MWCO). Following this, 
analysis by 10% SDS-PAGE gel and UV-Vis revealed conversion to 
the desired Her-Mestra conjugate with a PD-to-antibody ratio of ca. 
4. Then, aza-BODIPY 4 (8 eq from a 20 mM solution in DMSO) was 
added and the reaction mixture incubated at 21 °C for 6 h. The 
resulting mixture was then incubated for 10 minutes with protein A 
immobilised on beads and washed following manufacturer’s 
protocol. Following this, analysis by SDS-PAGE gel and UV-Vis 
revealed conversion to the desired Her-Mestra-aza-BODIPY 
conjugate 8 with a porphyrin-to-antibody ratio of ca. 4. 
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